Shares of Caribou Biosciences, a clinical-stage genome-editing biopharmaceutical company, saw a significant surge in premarket trading following news of a $25 million equity investment from drug giant Pfizer. This investment has been made at a healthy premium and has propelled Caribou's shares up by 36% to $5.56 during premarket trading. Pfizer purchased approximately 4.69 … [Read more...] about Caribou Biosciences Receives $25 Million Investment from Pfizer
